Managing HF Across the Spectrum

Catalog

Managing HF Across the Spectrum: From Recognizing Symptoms to Implementing Appropriate Treatment

What You Will Learn

Evaluate the epidemiology, risk factors, comorbidities, and community aspects associated with Heart Failure (HF) to determine best practices for care.
Distinguish pathophysiologic characteristics when evaluating and diagnosing HF, including current classifications, genotypes, and phenotypes, to best analyze HF risk stratification, prevention, and management strategies.
Incorporate Guideline-Directed Medical Therapy (GDMT), newer therapies, and interprofessional team strategies into treatment care plans for the management of HF to improve care coordination, communication, and patient outcomes.

Welcome Video

HF Overview

Self-Paced Learning

Coming Soon ➔

Gamification

HF Case Quest - Coming Soon ➔

Pathophysiology of HF

Animations

New Distinguishing Phenotypes in HF ➔ New Abnormal Ejection Fraction (EF) ➔

Infographics

Coming Soon ➔

Podcasts

The Pathophysiology Underlying HF Genotypes: Advances in Diagnosis and Management ➔

HF Prevention

Podcasts

HF Challenges in Rural and Underserved Communities ➔ How to Incorporate Lifestyle Modifications to Prevent HF ➔ Pharmacological and Nonpharmacological Interventions for the Prevention of HF ➔

Gamification

New Strategies for HF Prevention ➔

Challenges in HF Care

Podcasts

NEW Debunking Reasons for Delayed HF Treatment: BP Too Low (No Such Thing!) ➔ NEW Cr Too High (Almost No Such Thing) ➔ GDMT Will Not Delay HF Treatment ➔ Hyperkalemia in HFrEF and HFpEF ➔

Patient Case Quizzes

New Creatinine Too High ➔ Hypotension with HF ➔ Hyperkalemia in HF ➔ Management of HFpEF ➔

Recognizing and Managing Worsening HF

Live Webinars

Worsening HF: What to Do (Nomenclature and Epidemiology) ➔ Ask the Experts: What is the Emerging Science for Worsening Heart Failure? ➔

Webinars

New Nonpharmacologic Therapies For HF (To Do or Not To Do) ➔ New Additional Therapies For Worsening HF: Medications and Devices ➔

Mineralocorticoid Receptor Antagonists (MRAs) in HF

Self-Paced Lesson

NEW The Role of MRAs in the Management of HF ➔

Podcast

The Role of MRAs in the Management of HF ➔

Patient Case Quizzes

NEW Managing MRAs in HF Care ➔ NEW Optimizing MRA Use in HF Management ➔ Management of HFpEF with Hypertension ➔ HF Prevention in Patient with Coronary Artery Disease ➔ Preventing HF in Patient with Chronic Kidney Disease ➔

Guideline-Based Care

Podcasts

2024 ACC Expert Consensus Decision Pathway for Treatment of HFrEF ➔ 2023 ACC Expert Consensus Decision Pathway on Management of Patients with HFpEF ➔ 2022 AHA/ACC/HFSA Guideline for the Management of HF ➔

Infographic

Tackling Pivotal Issues in HFrEF: A Game Plan For Success ➔

Case Challenges and the HF Care Team

Gamifications

NEW Customizing the Treatment Plan for HF Patients: A Team Approach ➔

Mechanisms of Action (MOA)

Animated MOA Videos

Coming Soon ➔

We are grateful to these distinguished faculty who contributed to this collection:

Chair

Alison Bailey, MD, FACC
Melvin R. Echols, MD, FACC

Faculty

Vanessa Blumer, MD, FACC
Biykem Bozkurt, MD, PhD, FACC
Javed Butler, MBBS, MPH, MBA, FACC
Katherine Crawford, PharmD, BCCP, AACC
Leslie L. Davis, NP, PhD, FACC
Ersilia M. DeFilippis, MD, FACC, FAHA, FHFSA
Roberta Florido, MD, MHS
Michelle M. Kittleson, MD, PhD, FACC
Selma F. Mohammed, MBBS, FACC
George G. Sokos, DO, FACC
Estefania Oliveros Soles, MD, MSc, FACC, FAHA, FACP
Justin M. Vader, MD, FACC
Clyde W. Yancy, MD, MSc, MACC

Educational Grant Support Provided By: Bayer AG

Page Launched: August 28, 2025